This cross-sectional study describes the characteristics of abbreviated new drug applications approved by the US Food and Drug Administration, focusing on those with limited generic competition or with history of shortages.
No takes yet. Share an insight, caveat, or question.
Jiao et al. (2019) studied this question.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: